Trial reportIndian journal of ophthalmology2025
Application of S-100 absorbable hemostatic patch in endonasal endoscopic dacryocystorhinostomy: A randomized controlled trial.
Trial report in Indian journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the effect of S-100 absorbable hemostatic patch coverage on anastomotic mucosa in endonasal endoscopic dacryocystorhinostomy (En-DCR).
methodsTwo hundred and twenty-six patients with unilateral chronic dacryocystitis (CD) were randomly divided into two groups in a randomized controlled trial: the S-100 absorbable hemostatic patch group (group A) and the control group (group B). All patients underwent En-DCR. Group A received an S-100 absorbable hemostatic patch covering the wound approximately 2 mm around the ostium at the end of the En-DCR, whereas group B received no treatment. The patients were followed up for 12 months, and the mucosal epithelialization of the wound, granulation formation, bleeding, and success rate of ostial patency were compared between the two groups.
resultsOur study included 106 patients in group A and 102 patients in group B. After 2 weeks, the intact mucosal epithelium lining the ostia was 96 in group A and 77 in group B. At 12 months follow-up, there were five patients with scars (4.7%) and seven patients with granulomas (6.6%) in group A, compared with 17 patients with scars (16.7%) and 18 patients with granulomas (17.6%) in group B. There were significant differences in scar formation and granuloma formation between the two groups (P = 0.007 and 0.007, respectively). The success rate of anastomotic patency was 92.5% (98/106) in group A and 78.4% (80/102) in group B (P < 0.05). Postoperative bleeding was more substantial in group B than in group A (P < 0.05).
conclusionS-100 absorbable hemostatic patch cover can reduce the risk of postoperative bleeding and improve the success rate of EN-DCR treatment of CD by promoting healing of the anastomotic mucosa and preventing wound scar and granuloma formation after EN-DCR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.